HILDA/LIF urinary excretion during acute kidney rejection.
Recently, a new lymphokine called HILDA (human interleukin for DA cells) has been described and cloned. This cytokine, initially described to be produced by alloreactive T lymphocyte clones grown from a rejected human kidney allograft, is identical to other factors termed D-factor, differentiation-inducing factor, differentiation inhibitory activity, hepatocyte-stimulating factor III, and leukemia inhibitory factor. HILDA/LIF induces various effects on neural, hemopoietic, embryonic cells as well as on bone remodeling and acute phase protein synthesis in hepatocyte. In this study we demonstrate the presence of HILDA/LIF in the urine but not in the serum of kidney graft recipients during acute rejection episodes, whereas this lymphokine was detectable neither in the serum nor in the urine of kidney transplanted patients with stable renal function. These data reinforce the notion of a possible role for this lymphokine in the inflammatory and/or the immune response.
Taupin
J L
JL
Laboratoire d'Immunologie, Fondation Bergonié, Bordeaux, France.
Morel
D
D
Moreau
J F
JF
Gualde
N
N
Potaux
L
L
Bezian
J H
JH
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection; D006131:Growth Inhibitors / Q000097:blood / Q000652:urine*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015850:Interleukin-6; D007668:Kidney / Q000502:physiology; D016030:Kidney Transplantation / Q000276:immunology*; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000097:blood / Q000652:urine*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D006131:Growth Inhibitors; D007166:Immunosuppressive Agents; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D003404:Creatinine; D008775:Methylprednisolone